BACKGROUND: Clinical, pathologic, and molecular evidence indicate that bladder cancer is heterogeneous with pathologic/molecular features that define distinct subphenotypes with different prognoses. It is conceivable that specific patterns of genetic susceptibility are associated with particular subphenotypes. OBJECTIVE: To examine evidence for the contribution of germline genetic variation to bladder cancer heterogeneity. DESIGN, SETTING, AND PARTICIPANTS: The Spanish Bladder Cancer/EPICURO Study is a case-control study based in 18 hospitals located in five areas in Spain. Cases were patients with a newly diagnosed, histologically confirmed, urothelial cell carcinoma of the bladder from 1998 to 2001. Case diagnoses were reviewed and uniformly classified by pathologists following the World Health Organisation/International Society of Urological Pathology 1999 criteria. Controls were hospital-matched patients (n=1149). MEASUREMENTS: A total of 1526 candidate variants in 423 candidate genes were analysed. Three distinct subphenotypes were defined according to stage and grade: low-grade nonmuscle invasive (n=586), high-grade nonmuscle invasive (n=219), and muscle invasive (n=246). The association between each variant and subphenotype was assessed by polytomous risk models adjusting for potential confounders. Heterogeneity in genetic susceptibility among subphenotypes was also tested. RESULTS AND LIMITATIONS: Two established bladder cancer susceptibility genotypes, NAT2 slow-acetylation and GSTM1-null, exhibited similar associations among the subphenotypes, as did VEGF-rs25648, which was previously identified in our study. Other variants conferred risks for specific tumour subphenotypes such as PMS2-rs6463524 and CD4-rs3213427 (respective heterogeneity p values of 0.006 and 0.004), which were associated with muscle-invasive tumours (per-allele odds ratios [95% confidence interval] of 0.56 [0.41-0.77] and 0.71 [0.57-0.88], respectively) but not with non-muscle-invasive tumours. Heterogeneity p values were not robust in multiple testing according to their false-discovery rate. CONCLUSIONS: These exploratory analyses suggest that genetic susceptibility loci might be related to the molecular/pathologic diversity of bladder cancer. Validation through large-scale replication studies and the study of additional genes and single nucleotide polymorphisms are required. Copyright 2009 European Association of Urology. All rights reserved.
BACKGROUND: Clinical, pathologic, and molecular evidence indicate that bladder cancer is heterogeneous with pathologic/molecular features that define distinct subphenotypes with different prognoses. It is conceivable that specific patterns of genetic susceptibility are associated with particular subphenotypes. OBJECTIVE: To examine evidence for the contribution of germline genetic variation to bladder cancer heterogeneity. DESIGN, SETTING, AND PARTICIPANTS: The Spanish Bladder Cancer/EPICURO Study is a case-control study based in 18 hospitals located in five areas in Spain. Cases were patients with a newly diagnosed, histologically confirmed, urothelial cell carcinoma of the bladder from 1998 to 2001. Case diagnoses were reviewed and uniformly classified by pathologists following the World Health Organisation/International Society of Urological Pathology 1999 criteria. Controls were hospital-matched patients (n=1149). MEASUREMENTS: A total of 1526 candidate variants in 423 candidate genes were analysed. Three distinct subphenotypes were defined according to stage and grade: low-grade nonmuscle invasive (n=586), high-grade nonmuscle invasive (n=219), and muscle invasive (n=246). The association between each variant and subphenotype was assessed by polytomous risk models adjusting for potential confounders. Heterogeneity in genetic susceptibility among subphenotypes was also tested. RESULTS AND LIMITATIONS: Two established bladder cancer susceptibility genotypes, NAT2 slow-acetylation and GSTM1-null, exhibited similar associations among the subphenotypes, as did VEGF-rs25648, which was previously identified in our study. Other variants conferred risks for specific tumour subphenotypes such as PMS2-rs6463524 and CD4-rs3213427 (respective heterogeneity p values of 0.006 and 0.004), which were associated with muscle-invasive tumours (per-allele odds ratios [95% confidence interval] of 0.56 [0.41-0.77] and 0.71 [0.57-0.88], respectively) but not with non-muscle-invasive tumours. Heterogeneity p values were not robust in multiple testing according to their false-discovery rate. CONCLUSIONS: These exploratory analyses suggest that genetic susceptibility loci might be related to the molecular/pathologic diversity of bladder cancer. Validation through large-scale replication studies and the study of additional genes and single nucleotide polymorphisms are required. Copyright 2009 European Association of Urology. All rights reserved.
Authors: Tony Kwan; David Benovoy; Christel Dias; Scott Gurd; David Serre; Harry Zuzan; Tyson A Clark; Anthony Schweitzer; Michelle K Staples; Hui Wang; John E Blume; Thomas J Hudson; Rob Sladek; Jacek Majewski Journal: Genome Res Date: 2007-08 Impact factor: 9.043
Authors: Andrea Baccarelli; Lifang Hou; Jinbo Chen; Jolanta Lissowska; Emad M El-Omar; Paolo Grillo; Sara M Giacomini; Meredith Yaeger; Toralf Bernig; Witold Zatonski; Joseph F Fraumeni; Stephen J Chanock; Wong-Ho Chow Journal: Int J Cancer Date: 2006-10-15 Impact factor: 7.396
Authors: Elena López-Knowles; Silvia Hernández; Núria Malats; Manolis Kogevinas; Josep Lloreta; Alfredo Carrato; Adonina Tardón; Consol Serra; Francisco X Real Journal: Cancer Res Date: 2006-08-01 Impact factor: 12.701
Authors: Gilles Thomas; Kevin B Jacobs; Meredith Yeager; Peter Kraft; Sholom Wacholder; Nick Orr; Kai Yu; Nilanjan Chatterjee; Robert Welch; Amy Hutchinson; Andrew Crenshaw; Geraldine Cancel-Tassin; Brian J Staats; Zhaoming Wang; Jesus Gonzalez-Bosquet; Jun Fang; Xiang Deng; Sonja I Berndt; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; Richard B Hayes; David J Hunter; Stephen J Chanock Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: Montserrat Garcia-Closas; Per Hall; Heli Nevanlinna; Karen Pooley; Jonathan Morrison; Douglas A Richesson; Stig E Bojesen; Børge G Nordestgaard; Christen K Axelsson; Jose I Arias; Roger L Milne; Gloria Ribas; Anna González-Neira; Javier Benítez; Pilar Zamora; Hiltrud Brauch; Christina Justenhoven; Ute Hamann; Yon-Dschun Ko; Thomas Bruening; Susanne Haas; Thilo Dörk; Peter Schürmann; Peter Hillemanns; Natalia Bogdanova; Michael Bremer; Johann Hinrich Karstens; Rainer Fagerholm; Kirsimari Aaltonen; Kristiina Aittomäki; Karl von Smitten; Carl Blomqvist; Arto Mannermaa; Matti Uusitupa; Matti Eskelinen; Maria Tengström; Veli-Matti Kosma; Vesa Kataja; Georgia Chenevix-Trench; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Peter Devilee; Christi J van Asperen; Catharina E Jacobi; Rob A E M Tollenaar; Petra E A Huijts; Jan G M Klijn; Jenny Chang-Claude; Silke Kropp; Tracy Slanger; Dieter Flesch-Janys; Elke Mutschelknauss; Ramona Salazar; Shan Wang-Gohrke; Fergus Couch; Ellen L Goode; Janet E Olson; Celine Vachon; Zachary S Fredericksen; Graham G Giles; Laura Baglietto; Gianluca Severi; John L Hopper; Dallas R English; Melissa C Southey; Christopher A Haiman; Brian E Henderson; Laurence N Kolonel; Loic Le Marchand; Daniel O Stram; David J Hunter; Susan E Hankinson; David G Cox; Rulla Tamimi; Peter Kraft; Mark E Sherman; Stephen J Chanock; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Jan G M Klijn; Maartje J Hooning; Han Meijers-Heijboer; J Margriet Collee; Ans van den Ouweland; Andre G Uitterlinden; Jianjun Liu; Low Yen Lin; Li Yuqing; Keith Humphreys; Kamila Czene; Angela Cox; Sabapathy P Balasubramanian; Simon S Cross; Malcolm W R Reed; Fiona Blows; Kristy Driver; Alison Dunning; Jonathan Tyrer; Bruce A J Ponder; Suleeporn Sangrajrang; Paul Brennan; James McKay; Fabrice Odefrey; Valerie Gabrieau; Alice Sigurdson; Michele Doody; Jeffrey P Struewing; Bruce Alexander; Douglas F Easton; Paul D Pharoah Journal: PLoS Genet Date: 2008-04-25 Impact factor: 5.917
Authors: Matthew E Nielsen; Angela B Smith; Anne-Marie Meyer; Tzy-Mey Kuo; Seth Tyree; William Y Kim; Matthew I Milowsky; Raj S Pruthi; Robert C Millikan Journal: Cancer Date: 2013-10-10 Impact factor: 6.860
Authors: Montserrat Garcia-Closas; Yuanqing Ye; Nathaniel Rothman; Jonine D Figueroa; Núria Malats; Colin P Dinney; Nilanjan Chatterjee; Ludmila Prokunina-Olsson; Zhaoming Wang; Jie Lin; Francisco X Real; Kevin B Jacobs; Dalsu Baris; Michael Thun; Immaculata De Vivo; Demetrius Albanes; Mark P Purdue; Manolis Kogevinas; Ashish M Kamat; Seth P Lerner; H Barton Grossman; Jian Gu; Xia Pu; Amy Hutchinson; Yi-Ping Fu; Laurie Burdett; Meredith Yeager; Wei Tang; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Gerald Andriole; Robert Grubb; Amanda Black; Eric J Jacobs; W Ryan Diver; Susan M Gapstur; Stephanie J Weinstein; Jarmo Virtamo; David J Hunter; Neil Caporaso; Maria Teresa Landi; Joseph F Fraumeni; Debra T Silverman; Stephen J Chanock; Xifeng Wu Journal: Hum Mol Genet Date: 2011-08-08 Impact factor: 6.150
Authors: Xuejuan Jiang; J Esteban Castelao; Jian-Min Yuan; Mariana C Stern; David V Conti; Victoria K Cortessis; Malcolm C Pike; Manuela Gago-Dominguez Journal: Int J Cancer Date: 2011-05-09 Impact factor: 7.396